Evidence map›Paper›PMID 38031775›Full record

ReviewCurrent medicinal chemistry2024

Anti-Gene IGF-I Vaccines in Cancer Gene Therapy: A Review of a Case of Glioblastoma.

Annabelle Trojan, Yu-Chun Lone, Ignacio Briceno, Jerzy Trojan

Open access · greenAbstract readReviewCase Reports
PubMed Publisher
In one paragraph

Review in Current medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Annabelle TrojanINSERM UMR 1197, Cancer Center & University of Paris / Saclay, PO Box: 94802 Villejuif, France.
Yu-Chun LoneINSERM UMR 1197, Cancer Center & University of Paris / Saclay, PO Box: 94802 Villejuif, France.
Ignacio BricenoFaculty of Medicine, University of La Sabana, PO Box: 250008 Chia, Colombia.
Jerzy TrojanINSERM UMR 1197, Cancer Center & University of Paris / Saclay, PO Box: 94802 Villejuif, France.ORCID 0000-0001-5837-7669
Inserm · FRUniversidad de La Sabana · COUniversity of Cartagena · CO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveVaccines for the deadliest brain tumor - glioblastoma (GBM) - are generally based on targeting growth factors or their receptors, often using antibodies. The vaccines described in the review were prepared to suppress the principal cancer growth factor - IGF-I, using anti-gene approaches either of antisense (AS) or of triple helix (TH) type. Our objective was to increase the median survival of patients treated with AS and TH cell vaccines. METHODOLOGY: The cells were transfected

resultsThis immunogenicity proved to be stronger in IGF-I TH than in IGF-I AS-prepared cell vaccines, especially in TH / phytochemical cells. The AS and TH vaccines generated an important TCD8

conclusionThe anti-gene IGF-I vaccines continue to be applied in current GBM personalized medicine. Technical improvements in the preparation of AS and TH vaccines to increase MHC-1 and B7 immunogenicity have, in parallel, allowed to increase in the median survival of patients.

Indexed as

Brain NeoplasmsCancer VaccinesGlioblastomaVaccinesGenes, NeoplasmHumansInsulin-Like Growth Factor ITransfectionCancer VaccinesInsulin-Like Growth Factor IVaccinesanti-gene technologyCancer gene therapyglioblastomaIGF-Iimmuno-gene vaccinesignal transduction.

Identifiers

PMID38031775
OpenAlexW4389180610

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.